1. Home
  2. TRVI vs BSTZ Comparison

TRVI vs BSTZ Comparison

Compare TRVI & BSTZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

SELL

Current Price

$13.31

Market Cap

1.9B

Sector

Health Care

ML Signal

SELL

BSTZ

BlackRock Science and Technology Term Trust of Beneficial Interest

SELL

Current Price

$23.94

Market Cap

2.1B

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
TRVI
BSTZ
Founded
2011
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.1B
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
TRVI
BSTZ
Price
$13.31
$23.94
Analyst Decision
Strong Buy
Analyst Count
11
0
Target Price
★ $28.18
N/A
AVG Volume (30 Days)
★ 1.5M
191.0K
Earning Date
11-09-2026
01-01-0001
Dividend Yield
N/A
★ 8.31%
EPS Growth
★ 31.91
N/A
EPS
N/A
★ 0.71
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$34.88
Revenue Growth
N/A
N/A
52 Week Low
$9.82
$20.69
52 Week High
$20.22
$31.89

Technical Indicators

Market Signals
Indicator
TRVI
BSTZ
Relative Strength Index (RSI) 46.10 33.08
Support Level $13.00 $22.95
Resistance Level $13.55 $31.59
Average True Range (ATR) 0.88 0.92
MACD 0.06 -0.10
Stochastic Oscillator 20.92 6.50

Price Performance

Historical Comparison
TRVI
BSTZ

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

About BSTZ BlackRock Science and Technology Term Trust of Beneficial Interest

BlackRock Science and Technology Trust II is a diversified, closed-end management investment company. Its investment objectives are to provide total return and income mainly through long-term capital appreciation. The Trust invests a majority of its total assets in equity securities issued by U.S. and non-U.S. science and technology companies in any market capitalization range, selected for their rapid and sustainable growth potential from the development, advancement, and use of science and/or technology. Its investment portfolio comprises securities of companies from various industries, such as semiconductors and semiconductor equipment, software, communications equipment, IT services, and entertainment, etc.

Share on Social Networks: